Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | HPGD | P15428 | 4/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 6/20 | 0.36 |
| ▸ | MEN1 | O00255 | 4/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.36 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.36 |
| ▸ | HTT | P42858 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.35 |
| ▸ | GAA | P10253 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2512523 | 0.90 | SMN1; SMN2 (0.38) | SMN1; SMN2HPGDCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2124844 | 0.89 | AKT1 (0.32) | — | |
| SCHEMBL2124400 | 0.88 | SMN1; SMN2 (0.36) | SMN1; SMN2HPGDCYP1A2CYP3A4CYP2C19 | |
| SCHEMBL2123540 | 0.84 | KMT2A (0.34) | SMN1; SMN2HPGDCYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL2120890 | 0.80 | HCRTR1 (0.33) | KMT2AMEN1TSHR | |
| SCHEMBL2121865 | 0.78 | KDM4E (0.46) | SMN1; SMN2HPGDALDH1A1KDM4EMAPT | |
| SCHEMBL2124331 | 0.77 | ALDH1A1 (0.40) | SMN1; SMN2HPGDCYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL311517 | 0.72 | AKT1 (0.31) | — | |
| SCHEMBL2538401 | 0.70 | KDM4E (0.33) | SMN1; SMN2HPGDALDH1A1KDM4EMAPT | |
| SCHEMBL2533055 | 0.69 | KDM4E (0.35) | SMN1; SMN2HPGDALDH1A1KDM4EMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2379550-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | Glaxo Group Limited (GB) | 2011-10-26 | — | — | EP | disclosed |
| US-20110257198-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257198-A1 | PIPERIDINE DERIVATIVES USEFUL AS OREXIN ANTAGONISTS | HCRTR2, HCRTR1, VIPR2 | SMN1; SMN2 2062/4885HPGD 732/4885CYP1A2 3216/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.